May 29, 2015 at 09:07 | Source: PTI
Net sales of the company stood at Rs 3,142.46 crore for the fourth quarter, while the same stood at Rs 2,305.88 crore during the corresponding period of previous year, Aurobindo Pharma said in a filing to the BSE.
May 29, 2015 at 07:59 | Source: CNBC-TV18
Tata Motors | Kotak Mahindra Bank | Coal India | ONGC | HPCL | GMR Infra | Bank of India | NMDC | Global Offshore | SpiceJet | KEI Industries | Hindustan Copper | Dishman Pharma | Dhanlaxmi Bank | Crompton Greaves | Aurobindo Pharma | Cummins India and Kohinoor Foods are stocks, which are in the news today.
May 28, 2015 at 12:47 | Source: CNBC-TV18
R Sreesankar, head-institutional equities at Prabhudas Lilladher is of the view that Aurobindo Pharma is the top pick.
May 28, 2015 at 07:58 | Source: CNBC-TV18
Gammon Infra | Cipla | GAIL | United Spirits | TCS | Infosys | Jindal Steel | Tata Chemicals | AstraZeneca Pharma | Novartis India | Adlabs Entertainment | Hotel Leela | Abbott India | Dhampur Sugar | SJVN | Trident | Trent | Bata India | Ess Dee Aluminium | Bhushan Steel and JBF Industries are stocks, which are in the news today.
May 27, 2015 at 17:09 | Source: CNBC-TV18
Aurobindo Pharma's fourth quarter profit is seen falling 19 percent year-on-year to Rs 408 crore, according to a CNBC-TV18 poll.
May 26, 2015 at 09:32 | Source: CNBC-TV18
CNBC-TV18s Varinder Bansal gives a check on the best & worst performing stocks in this last one year of Modi government.
May 23, 2015 at 12:34 | Source: PTI
Private sector electricity producer Tata Power will move out of the stock market benchmark index Sensex and will be replaced by drugmaker Lupin.
May 20, 2015 at 13:08 | Source: CNBC-TV18
R Sreesankar, Head-Institutional Equities at Prabhudas Lilladher is of the view that Glenmark Pharma, Dr Reddy's Laboratories and Aurobindo Pharma are the top picks from the pharma space.
May 20, 2015 at 08:36 | Source: CNBC-TV18
We see earnings improving only late 2015 and stock market returns being back-ended with a flat to slightly negative phase in Q2 & Q3 of 2015, says Anand Kumar of BofA ML.
May 19, 2015 at 16:30 | Source: CNBC-TV18
Rahul Mohindar of viratechindia.com feels that Aurobindo Pharma may test Rs 1480-1490 in the medium-term.